Cost utility of a pharmacist-led minor ailment service compared with usual pharmacist care

Table 5 Incremental analysis: Cost-utility (base case) and cost-effectiveness results

	Mean cost per patient (SD)	Total outcome	Inc. cost (AUD)	Inc. outcome	ICER (AUD/outcome)
Outcome = QALY
UC	$19.75 (SD $7.47)	0.0264
MAS	$26.88 (SD $7.62)	0.0296	$7.14	0.003	$2277
Outcome = episode of appropriate pharmacist care (care meeting agreed treatment pathways)
UC	$19.75 (SD $7.47)	0.676
MAS	$26.88 (SD $7.62)	0.866	$7.14	0.191	$37.42
Outcome = extra patient achieving symptom resolution
UC	$19.75 (SD $7.47)	0.738
MAS	$26.88 (SD $7.62)	0.750	$7.14	0.012	$586.88

AUD Australian dollars, ICER incremental cost effectiveness ratio, MAS minor ailment service, QALY quality adjusted life year, UC usual pharmacist care
The costs used in the cost utility and cost effectiveness evaluations for MAS is $26.88 rather than $29.56 as a result of the decision tree modelled analysis that considers the proportion of patients in each arm receiving an outcome instead of the mean costs stated above. Similarly, UC is $19.75 instead of $22.28

ISSN: 1478-7547